Clinical Trials
7 trialsNCT07297667 2026-05-12
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Canadian Cancer Trials Group
Phase 1 Not yet recruiting
NCT07523529 2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2 Recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT04551885 2023-09-21
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT05069935 2023-09-21
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT04639245 2023-08-03
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Terminated